High expression of AURKA and AURKB is associated with unfavorable cytogenetic abnormalities and high white blood cell count in patients with acute myeloid leukemia

Autor(es)

Lucena-Araujo, Antonio R. ^[1] ; de Oliveira, Fabio Morato ^[1] ; Leite-Cueva, Sabrina Dias ^[2] ; dos Santos, Guilherme Augusto ^[1] ; Falcao, Roberto Passeto ^[1] ; Rego, Eduardo Magalhaes ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Med Sch Ribeirao Preto, Natl Inst Sci & Technol Cell Based Therapy, Div Hematol, Dept Internal Med, BR-14048900 Ribeirao Preto - Brazil

^[2] Univ Sao Paulo, Med Sch Ribeirao Preto, Natl Inst Sci & Technol Cell Based Therapy, Dept Genet, BR-14048900 Ribeirao Preto - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Leukemia Research; v. 35, n. 2, p. 260-264, FEB 2011.
• Citações Web of Science: 36

Resumo

In the present study, we analyzed AURKA and AURKB gene expression in 70 acute myeloid leukemia (AML) patients. There was no difference between leukemic samples and bone marrow mononuclear cells (BMMCs, n = 8) or CD34(+) progenitors (n = 10) from healthy donors. High white blood cells (WBC) counts were observed in the AURKA(+) and AURKB(+) groups, but no significant differences regarding age, gender, platelet counts or frequency of FLT3-ITD mutations. AURKA, but not AURKB, expression was independently associated with high WBC counts (OR: 3.15, 95% CI 1.07-9.24, p = 0.03). Moreover, the majority of cases that overexpressed AURKA and AURKB presented unfavorable cytogenetic abnormalities (p < 0.001). In conclusion, we described a significant association between overexpression of AURKA/B and cytogenetics findings in AML, which may be relevant to new therapeutic approaches, based on Aurora kinase inhibitors. (C) 2010 Elsevier Ltd. All rights reserved. (AU)

• Processo FAPESP: 07/55067-1 - Analise in vivo e in vitro da acao oncogenica da forma delta n do gene p73 na leucemia promielocitica aguda.
• Beneficiário: Antonio Roberto Lucena de Araújo
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 07/52462-7 - Citogenética clássica e cariótipo espectral (SKY) aplicados à caracterização da leucemia linfocítica crônica B (LLC-B) imunoestimulada pelo oligonucleotídeo DSP30 e IL-2
• Beneficiário: Fábio Morato de Oliveira
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado